CirChem AB AI Stock Analysis
Want to see SE:CIRCHE full AI Analyst Report?
CirChem AB (CIRCHE) AI Stock Analysis
CirChem AB
(Nasdaq OMX AB:CIRCHE)
The overall score is at the lowest possible level, reflecting a company in severe financial distress. The most significant factor is the fundamentally broken business model, evidenced by gross margins exceeding -200% and an unsustainable cash burn rate that is rapidly consuming equity. This is compounded by a persistently bearish technical trend, with the stock trading far below key moving averages. The negative P/E ratio and lack of dividend yield offer no valuation support. The company faces a high risk of financial failure without an immediate and radical operational turnaround.
CirChem AB (CIRCHE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 23.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 49.44K
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- -0.14
- Revenue Growth
- -40.15%
- EPS Growth
- -127.64%
- Country
- Sweden
- Employees
- 11
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Waste Management
CirChem AB Business Overview & Revenue Model
Company Description
CirChem AB (publ) focuses on the reclamation of spent industrial solvents across Sweden. The company collects and purifies these used chemicals, preparing them for reuse, and furthermore produces other chemical solutions such as windshield washer flu...
CirChem AB Financial Statement Overview
Summary
Financial performance is critically distressed. The income statement shows a gross margin of -202.5% and net margin of -215.0%, indicating the core business model is broken. The cash flow statement is equally alarming, with deeply negative operating and free cash flow that exceeds the net loss. The only mitigating factor is a low debt-to-equity ratio of 0.28 on the balance sheet, but equity is eroding rapidly. Overall, the company faces a severe profitability and cash burn crisis.
Income Statement
8Very NegativeBalance Sheet
45NeutralCash Flow
5Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.50M | 9.96M | 20.66M | 5.75M | 590.62K | 85.55K |
| Gross Profit | -17.21M | -7.93M | 19.53M | 3.04M | 2.92M | 2.62M |
| EBITDA | -16.09M | -10.12M | 374.00K | -15.52M | -19.87M | -16.74M |
| Net Income | -18.28M | -12.05M | -1.07M | -17.14M | -25.50M | -19.48M |
Balance Sheet | ||||||
| Total Assets | 64.23M | 69.47M | 61.18M | 59.11M | 50.30M | 52.14M |
| Cash, Cash Equivalents and Short-Term Investments | 10.66M | 13.65M | 11.93M | 16.58M | 9.78M | 14.57M |
| Total Debt | 11.98M | 20.52M | 8.92M | 8.92M | 1.75M | 2.00M |
| Total Liabilities | 21.65M | 25.14M | 15.49M | 24.00M | 25.17M | 25.77M |
| Stockholders Equity | 42.59M | 44.33M | 45.68M | 35.10M | 25.13M | 26.37M |
Cash Flow | ||||||
| Free Cash Flow | -18.26M | -20.57M | -12.85M | -27.48M | -25.27M | -5.47M |
| Operating Cash Flow | -17.31M | -13.70M | -6.38M | -26.68M | -21.49M | -2.78M |
| Investing Cash Flow | -954.00K | -6.88M | -6.47M | -798.49K | -3.78M | -2.69M |
| Financing Cash Flow | 15.34M | 22.29M | 8.20M | 34.29M | 20.48M | -2.04M |
CirChem AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CIRCHE, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.50, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.42 is Neutral, neither overbought nor oversold. The STOCH value of 14.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CIRCHE.
CirChem AB Peers Comparison
Overall Rating
SE:BIOEX46Neutral
SE:FREEM40Underperform
SE:SALT.B39Underperform
SE:SES38Underperform
SE:CIRCHE37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 46Neutral | SEK 126.87M | -5.92 | -116.56% | ― | -37.50% | 1.01% | |
| 40Underperform | SEK 261.40M | -2.25 | -52.39% | ― | -9.02% | 29.77% | |
| 39Underperform | SEK 863.97M | -9.50 | -44.16% | ― | -20.05% | -27.10% | |
| 38Underperform | SEK 118.26M | -0.22 | -305.30% | ― | -70.67% | -264.87% | |
| 37Underperform | SEK 23.61M | -0.88 | -44.41% | ― | -40.15% | -127.64% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:CIRCHE | CirChem AB | 0.37 | -0.42 | -53.47% | |
| SE:SES | Scandinavian Enviro Systems AB | 0.09 | -0.73 | -89.27% | |
| SE:FREEM | Freemelt Holding AB | 1.15 | -0.31 | -21.37% | |
| SE:SALT.B | SaltX Technology Holding AB Class B | 3.75 | -1.17 | -23.74% | |
| SE:BIOEX | Bioextrax AB | 2.57 | 0.48 | 23.14% | |
| SE:META | Metacon AB | 0.09 | -0.46 | -83.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
